Dyadic International（股票代码：DYAI）宣布，已向FBS与Scripps研究机构成功交付由C1蛋白表达平台生产的Bundibugyo埃博拉病毒抗原。这批抗原将用于临床前评估阶段，旨在探索针对该病毒的潜在疫苗或治疗策略。此举标志着公司在利用创新C1技术推动抗病毒研发方面迈出关键一步。该交付成果有望为后续的免疫原性研究与动物模型试验奠定基础，进一步验证C1平台在应对高致病性病原体中的适用性。
Dyadic International（股票代码：DYAI）宣布，已向FBS与Scripps研究机构成功交付由C1蛋白表达平台生产的Bundibugyo埃博拉病毒抗原。这批抗原将用于临床前评估阶段，旨在探索针对该病毒的潜在疫苗或治疗策略。此举标志着公司在利用创新C1技术推动抗病毒研发方面迈出关键一步。该交付成果有望为后续的免疫原性研究与动物模型试验奠定基础，进一步验证C1平台在应对高致病性病原体中的适用性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.